Disturbances in melatonin secretion and the efficacy of replacement therapy in sleep disorders

Close metadata

Recommended articles:

Cognitive impairment in cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16

Respiratory-syncitial virus: biology, genetic diversity and perspective control preparations. Molecular Genetics, Microbiology and Virology. 2024;(1):16-24

Impact of bullying on adolescents’ health: association with psychosomatic complaints. Russian Journal of Preventive Medicine. 2024;(3):52-58

Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology. 2024;(2):39-45

Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79

Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126

Ultrastructural characteristics of transplantable B16 melanoma cells under the influence of constant darkness. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):21-29

Melatonin at the health-resort stage of treatment and rehabilitation in national practice. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):55-59

Comorbid disorders and risk factors for neiropathic pain in distal diabetic polyneuropathy. Russian Journal of Pain. 2024;(2):41-48

Human diseases treatment via enema fecal microbiota transplantation. Methodological recommendations. Russian Journal of Preventive Medicine. 2024;(6):79-87

The review presents data on the dependence of endogenous melatonin synthesis on the time of day, age, pineal gland size, lighting conditions, administration of beta-blockers and a number of other medications. The results of studies on parasecretion and efficacy of exogenous melatonin use in sleep-wake cycle disturbances, insomnia, neurodegeneration, diabetes mellitus and oncological diseases are discussed.

Keywords:

melatonin

6-sulfatoxymelatonin excretion

therapy

sleep disorders

Authors:

Zybina N.N.

Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia, Saint-Petersburg, Russia

Tikhomirova O.V.

List of references:

Anisimov VN. Melatonin: rol’ v organizme, primenenie v klinike. SPb.: Sistema; 2007. (In Russ.)
Koval’zon VM. Osnovy somnologii: fiziologiya i neirokhimiya tsikla «bodrstvovanie—son. M.: Binom; 2012. (In Russ.)
Hasegawa A, Ohtsubo K, Mori W. Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsy cases. Brain Res. 1987;409(2):343-349.
Arendt J. Melatonin and human rhythms. Chronobiol Int. 2006;23(1-2):21-37.
Bergiannaki JD, Soldatos CR, Paparrigopoulos TJ, Syrengelas M, Stefanis CN. Low and high melatonin excretors among healthy individuals. J Pineal Res. 1995;18(3):159-164.
Sigurdardottir LG, Markt SC, Sigurdsson S, Aspelund T, Fall K, Schernhammer E, Rider JR, Launer L, Harris T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA. Pineal Gland Volume Assessed by MRI and its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. J Biol Rhythms. 2016;31(5):461-469.
Kunz D, Schmitz S, Mahlberg R, Mohr A, Stöter C, Wolf KJ, Herrmann WM. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology. 1999;21(6):765-772.
Ozguner F, Koyu A, Cesur G. Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health. 2005;21(1/2):21-26.
Kuhlwein E, Hauger RL, Irwin MR. Abnormal nocturnal melatonin secretion and disordered sleep in abstinent alcoholics. Biol Psychiatry. 2003; 54(12):1437-1443.
Cowen PJ, Bevan JS, Gosden B, Elliott SA. Treatment with beta-adrenoceptor blockers reduces plasma melatonin concentration. Br J Clin Pharmacol. 1985;19(2):258-260.
Rommel T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm Gen Sect. 1994;95(1):39-48.
McIntyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry. 1988;24(1):108-112.
Murphy PJ, Badia P, Myers BL, Boecker MR, Wright KP Jr. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav. 1994;55(6):1063-1066.
Surrall K, Smith JA, Bird H, Okala B, Othman H, Padwick DJ. Effect of ibuprofen and indomethacin on human plasma melatonin. J Pharm Pharmacol. 1987;39(10):840-843.
Gooley JJ, Chamberlain K, Smith KA, Khalsa SB, Rajaratnam SM, Van Reen E, Zeitzer JM, Czeisler CA, Lockley SW. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011;96(3):463-472.
Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H, Manchester LC. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Review Crit Rev Oncog. 2007:13(4):303-328.
McMullan CJ, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013;309(13):1388-1396. https://doi.org/10.1001/jama.2013.2710.
Możdżan M, Możdżan M, Chałubiński M. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch Med Sci. 2014;10(4):669-675.
Kalinchenko SYu, Tyuzikov IA. Defitsit melatonina, ozhirenie i insulinorezistentnost’: ochevidnye i neochevidnye vzaimosvyazi. Voprosy dietologii. 2017;7(2):23-32. (In Russ.)
Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta. 2006;1757(5/6):573-589.
Mazzoccoli G, Carughi S, De Cata A, La Viola M, Vendemiale G. Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit. 2005;11(6):284-288.
Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23(1):15-19.
Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris). 2007;55:201-204.
Plog BA, Nedergaard M. The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future. Annu Rev Pathol. 2018;13:379-394.
León J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005;38:1-9.
Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P. Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer’s disease. Chronobiol Int. 2001;18(3): 513-524.
Musiek E, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease. Exp Mol Med. 2015;47(3):148.
Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin Therapy in Patients with Alzheimer’s Disease. Antioxidants (Basel). 2014;3(2):245-277.
McGrane IR, Leung JG, Louis EK, Boeve BF. Melatonin Therapy for REM Sleep Behavior Disorder: A Critical Review of Evidence. Sleep Med. 2015;16(1):19-26.
Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in clinical trial of melatonin replacement. Sleep. 1998;21:52-68.
Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin exretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91-95.
Ellis CM, Lemmens G, Parkes D. Melatonin and insomnia. J Sleep Res. 1996;5:61-65.
Poluektov MG, Levin YaI, Boiko AN, Sroromets AA, Belskaja GN, Gustov AV, Doronin BM, Poverennova IE, Spirin NN, Yakupov EZ. Rezul’taty rossiiskogo mul’titsentrovogo issledovaniya effektivnosti i bezopasnosti melaksena (melatonin) dlya lecheniya narushenii sna u patsientov s khronicheskoi tserebral’noi sosudistoi nedostatochnost’yu. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(9):26-31. (In Russ.)
Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The Safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169-175. https://doi.org/10.1007/s40261-015-0368-5
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):63773. https://doi.org/10.1371/journal.pone.0063773
Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91-95.
León J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Case-study of evening melatonin concentration in primary insomnia. Brit Med J. 1996;312(7041):1263-1264.
Tikhomirova OV, Butyrina EV, Zybina NN, Frolova MYu. Otsenka ekskretsii osnovnogo metabolita melatonina v diagnostike psikhofiziologicheskoi insomnii Evaluation of excretion of the main melatonin metabolite in the diagnosis of psychophysiological insomnia. Meditsinskii alfavit. Sovremennaya laboratoriya. 2013;3(16):62-68. (In Russ.)
Lushington K, Lack L, Kennaway D, Rogers N, Heuvel C, Dawson D. 6-Sulfatoxymelatonin excretion and self-reported sleep in good sleeping controls and 55—80-year-old insomniacs. J Sleep Res. 1998;7(2):75-83.
Lushington K, Dawson D, Kennaway DJ, Lack L. The relationship between 6-sulphatoxymelatonin and polysomnographic sleep in good sleeping controls and wake maintence insomniacs, aged 55—80 years. J Sleep Res. 1999;8(1):57-64.
Hajak G, Rodenbeck A, Staedt J. Nocturnal plasma melatonin excretion in patients suffering from chronic primary insomnia. J Pineal Res. 1995; 19(3):116-122.
Rodenbeck A, Huether G, Rüther E, Hajak G. Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders. Review. Adv Exp Med Biol. 1999;467:89-93.
Pierpaoli W, Bulian D, Bulian G, Kistler G. Thyrotropin-Releasing Hormone Accelerates and Enhances the Age-Postponing Effects of Melatonin. Journal of Anti-Aging Medicine. 1999;2(4):343-348.

Close metadata